TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Flexibly-Dosed Combination Pharmacotherapy Versus Standard-Dosed Nicotine Patch Alone for Smokers With Medical Illness
Brief Summary: Randomized clinical trial to evaluate a flexibly-dosed-3-medication combination for up to 6 months in smokers with medical illness


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Arm Label: NRT arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy (NRT) | Arm Label: NRT and HIV Tailored Quit Smoking Counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy (NRT), Behavioral: HIV Tailored Quit Smoking Counseling | Arm Label: Varenicline (VR) Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Varenicline (VR) and HIV Tailored Quit Smoking Counseling; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Behavioral: HIV Tailored Quit Smoking Counseling | Intervention Type: DRUG; Name: Nicotine Replacement Therapy (NRT); Assigned to Arm(s): NRT and HIV Tailored Quit Smoking Counseling, NRT arm | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline (VR) Arm, Varenicline (VR) and HIV Tailored Quit Smoking Counseling | Intervention Type: BEHAVIORAL; Name: HIV Tailored Quit Smoking Counseling; Assigned to Arm(s): NRT and HIV Tailored Quit Smoking Counseling, Varenicline (VR) and HIV Tailored Quit Smoking Counseling
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nicotine patch, nicotine inhaler, bupropion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch | Intervention Type: DRUG; Name: Nicotine patch, nicotine inhaler, bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nicotine patch; Assigned to Arm(s): 2
D: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate (CP-526, 555-18) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: varenicline tartrate (CP-526, 555-18); Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Flexibly-Dosed Combination Pharmacotherapy Versus Standard-Dosed Nicotine Patch Alone for Smokers With Medical Illness
Brief Summary: Randomized clinical trial to evaluate a flexibly-dosed-3-medication combination for up to 6 months in smokers with medical illness


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nicotine patch, nicotine inhaler, bupropion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch | Intervention Type: DRUG; Name: Nicotine patch, nicotine inhaler, bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nicotine patch; Assigned to Arm(s): 2
B: Arm Label: Varenicline + Placebo Patch; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Placebo Patch, Behavioral: Questionnaires, Behavioral: Counseling Sessions, Other: Lab Session, Other: Saliva Test | Arm Label: Nicotine Patch + Placebo Tablet; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Drug: Placebo Tablet, Behavioral: Questionnaires, Behavioral: Counseling Sessions, Other: Lab Session, Other: Saliva Test | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Nicotine Patch + Placebo Tablet | Intervention Type: DRUG; Name: Placebo Patch; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Placebo Tablet; Assigned to Arm(s): Nicotine Patch + Placebo Tablet | Intervention Type: BEHAVIORAL; Name: Questionnaires; Assigned to Arm(s): Nicotine Patch + Placebo Tablet, Varenicline + Placebo Patch | Intervention Type: BEHAVIORAL; Name: Counseling Sessions; Assigned to Arm(s): Nicotine Patch + Placebo Tablet, Varenicline + Placebo Patch | Intervention Type: OTHER; Name: Lab Session; Assigned to Arm(s): Nicotine Patch + Placebo Tablet, Varenicline + Placebo Patch | Intervention Type: OTHER; Name: Saliva Test; Assigned to Arm(s): Nicotine Patch + Placebo Tablet, Varenicline + Placebo Patch
C: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Flexibly-Dosed Combination Pharmacotherapy Versus Standard-Dosed Nicotine Patch Alone for Smokers With Medical Illness
Brief Summary: Randomized clinical trial to evaluate a flexibly-dosed-3-medication combination for up to 6 months in smokers with medical illness


Options:
A: Arm Label: Bupropion (Wellbutrin-SR); Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion-SR | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bupropion-SR; Assigned to Arm(s): Bupropion (Wellbutrin-SR) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Matching Placebo
B: Arm Label: Effectiveness of Nicotine patch only; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Arm Label: Effectiveness of Combination NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine lozenge, Drug: Nicotine Patch | Arm Label: Effectiveness of Varenicline [Chantix]; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Effectiveness of Varenicline [Chantix] | Intervention Type: DRUG; Name: Nicotine lozenge; Assigned to Arm(s): Effectiveness of Combination NRT | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Effectiveness of Combination NRT, Effectiveness of Nicotine patch only
C: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nicotine patch, nicotine inhaler, bupropion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch | Intervention Type: DRUG; Name: Nicotine patch, nicotine inhaler, bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nicotine patch; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Flexibly-Dosed Combination Pharmacotherapy Versus Standard-Dosed Nicotine Patch Alone for Smokers With Medical Illness
Brief Summary: Randomized clinical trial to evaluate a flexibly-dosed-3-medication combination for up to 6 months in smokers with medical illness


Options:
A: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm III; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): Arm III | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Matched Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo for varenicline; Assigned to Arm(s): Matched Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: nicotine transdermal patch | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine transdermal patch | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: nicotine transdermal patch; Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nicotine patch, nicotine inhaler, bupropion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch | Intervention Type: DRUG; Name: Nicotine patch, nicotine inhaler, bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nicotine patch; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Flexibly-Dosed Combination Pharmacotherapy Versus Standard-Dosed Nicotine Patch Alone for Smokers With Medical Illness
Brief Summary: Randomized clinical trial to evaluate a flexibly-dosed-3-medication combination for up to 6 months in smokers with medical illness


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nicotine patch, nicotine inhaler, bupropion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch | Intervention Type: DRUG; Name: Nicotine patch, nicotine inhaler, bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nicotine patch; Assigned to Arm(s): 2
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Varenicline | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Sugar pill
C: Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): N/A
D: Arm Label: Brief Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Extended NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Tailored/No Extended NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Extended Tailored Counseling + NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Intervention Type: DRUG; Name: Nicotine polacrilex, Bupropion; Assigned to Arm(s): Brief Treatment, Extended NRT, Extended Tailored Counseling + NRT, Tailored/No Extended NRT

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Study of SEP-190 (Eszopiclone) in Patients With Insomnia
Brief Summary: The purpose of this study is to evaluate the long-term safety of eszopiclone (2, 3 mg) in non-elderly patients with insomnia and eszopiclone (1, 2 mg) in elderly patients with insomnia.


Options:
A: Arm Label: Eszopiclone 1 mg- Elderly; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone 1 mg- Elderly | Arm Label: Eszopiclone 2 mg- Elderly; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone 2 mg- Elderly | Arm Label: Eszopiclone 2 mg- Non-elderly; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone 2 mg- Non-elderly | Arm Label: Eszopiclone 3 mg- Non-elderly; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone 3 mg- Non-elderly | Intervention Type: DRUG; Name: Eszopiclone 1 mg- Elderly; Assigned to Arm(s): Eszopiclone 1 mg- Elderly | Intervention Type: DRUG; Name: Eszopiclone 2 mg- Elderly; Assigned to Arm(s): Eszopiclone 2 mg- Elderly | Intervention Type: DRUG; Name: Eszopiclone 3 mg- Non-elderly; Assigned to Arm(s): Eszopiclone 3 mg- Non-elderly | Intervention Type: DRUG; Name: Eszopiclone 2 mg- Non-elderly; Assigned to Arm(s): Eszopiclone 2 mg- Non-elderly
B: Arm Label: MBSR; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-Based Stress Reduction | Arm Label: PCT Sleeping Pills; Type: ACTIVE_COMPARATOR; Interventions: Drug: eszopiclone | Intervention Type: BEHAVIORAL; Name: Mindfulness-Based Stress Reduction; Assigned to Arm(s): MBSR | Intervention Type: DRUG; Name: eszopiclone; Assigned to Arm(s): PCT Sleeping Pills
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Eszopiclone, Drug: Fluoxetine | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluoxetine, Drug: Placebo | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
D: Arm Label: eszopiclone; Type: EXPERIMENTAL; Interventions: Drug: eszopiclone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: eszopiclone; Assigned to Arm(s): eszopiclone | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Magnetic Seizure Therapy (MST) in Refractory Major Depression
Brief Summary: The investigators intend to test in a single center, clinical pilot efficacy study the primary hypothesis that Magnetic Seizure Therapy (MST) as add-on therapy to a controlled pharmacotherapy is efficacious in the treatment of refractory major depression assessed with the Hamilton Depression Rating Scale (HAMD).


Options:
A: Arm Label: Magnetic Seizure Therapy Group; Type: N/A; Interventions: N/A | Arm Label: Electroconvulsive Therapy Group; Type: N/A; Interventions: N/A
B: Arm Label: Magnetic Seizure Therapy (MST); Type: EXPERIMENTAL; Interventions: Device: Tonica MagPro MST | Arm Label: Electroconvulsive Therapy (ECT); Type: ACTIVE_COMPARATOR; Interventions: Device: Thymatron | Intervention Type: DEVICE; Name: Thymatron; Assigned to Arm(s): Electroconvulsive Therapy (ECT) | Intervention Type: DEVICE; Name: Tonica MagPro MST; Assigned to Arm(s): Magnetic Seizure Therapy (MST)
C: Arm Label: Magnetic Seizure Therapy (MST); Type: EXPERIMENTAL; Interventions: Device: Magnetic Seizure Therapy | Arm Label: Electroconvulsive Therapy (ECT); Type: ACTIVE_COMPARATOR; Interventions: Device: Electroconvulsive Therapy | Intervention Type: DEVICE; Name: Magnetic Seizure Therapy; Assigned to Arm(s): Magnetic Seizure Therapy (MST) | Intervention Type: DEVICE; Name: Electroconvulsive Therapy; Assigned to Arm(s): Electroconvulsive Therapy (ECT)
D: Arm Label: Magnetic Seizure Therapy; Type: EXPERIMENTAL; Interventions: Device: Magnetic Seizure Therapy (MagPro MST) | Intervention Type: DEVICE; Name: Magnetic Seizure Therapy (MagPro MST); Assigned to Arm(s): Magnetic Seizure Therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exercise Dose and Nonalcoholic Fatty Liver Disease
Brief Summary: The purpose of this research is to provide a better understanding of how exercise (walking) affects non-alcoholic fatty liver disease (NAFLD) in overweight people. NAFLD, which is common in obese people, occurs when the liver has too much fat.


Options:
A: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: exercise | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): Exercise
B: Arm Label: Glucose; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Glucose | Arm Label: Fructose; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Fructose | Intervention Type: DIETARY_SUPPLEMENT; Name: Glucose; Assigned to Arm(s): Glucose | Intervention Type: DIETARY_SUPPLEMENT; Name: Fructose; Assigned to Arm(s): Fructose
C: Arm Label: Intensive exercise; Type: EXPERIMENTAL; Interventions: Other: Intensive exercise | Arm Label: Lifestyle counseling; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Regular exercise; Type: EXPERIMENTAL; Interventions: Other: Conventional exercise | Intervention Type: OTHER; Name: Intensive exercise; Assigned to Arm(s): Intensive exercise | Intervention Type: OTHER; Name: Conventional exercise; Assigned to Arm(s): Regular exercise
D: Arm Label: Low glycemic index dietary intervention program; Type: ACTIVE_COMPARATOR; Interventions: Other: Low glycemic index dietary intervention program | Arm Label: Simple lifestyle advice; Type: PLACEBO_COMPARATOR; Interventions: Other: simple lifestyle advice | Intervention Type: OTHER; Name: Low glycemic index dietary intervention program; Assigned to Arm(s): Low glycemic index dietary intervention program | Intervention Type: OTHER; Name: simple lifestyle advice; Assigned to Arm(s): Simple lifestyle advice

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to demonstrate superiority of percutaneous posterior tibial nerve stimulation (PTNS) therapy compared to sham therapy for the treatment of patients with overall bladder (OAB) symptoms.


Options:
A: Arm Label: Urgent PC; Type: ACTIVE_COMPARATOR; Interventions: Device: Urgent PC Neuromodulation System | Arm Label: Sham / Placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Urgent PC Neuromodulation System; Assigned to Arm(s): Urgent PC
B: Arm Label: Urgent PC treatment arm; Type: EXPERIMENTAL; Interventions: Device: Urgent PC Neuromodulation System, Drug: Tolterodine | Intervention Type: DEVICE; Name: Urgent PC Neuromodulation System; Assigned to Arm(s): Urgent PC treatment arm | Intervention Type: DRUG; Name: Tolterodine; Assigned to Arm(s): Urgent PC treatment arm
C: Arm Label: Urgent PC; Type: ACTIVE_COMPARATOR; Interventions: Device: Urgent PC | Intervention Type: DEVICE; Name: Urgent PC; Assigned to Arm(s): Urgent PC
D: Arm Label: Percutaneus Stimulation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Percutaneus Stimulation | Arm Label: Transcutaneous Stimulation; Type: EXPERIMENTAL; Interventions: Device: Transcutaneous Stimulation | Intervention Type: DEVICE; Name: Transcutaneous Stimulation; Assigned to Arm(s): Transcutaneous Stimulation | Intervention Type: PROCEDURE; Name: Percutaneus Stimulation; Assigned to Arm(s): Percutaneus Stimulation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low Molecular Weight Heparin in Advanced Non Small Cell Lung Cancer (NSCLC): a Randomized Open Label Phase III Study Evaluating the Effect of Enoxaparin (Clexane) on Survival and Symptom Control in Patients With Stage IIIB and IV NSCLC Undergoing a Cisplatin Based First Line Chemotherapy: the SYRINGES Trial
Brief Summary: Rationale: a number of recent phase III randomized trials have shown a survival benefit of a treatment with subcutaneous low-molecular weight heparin in patients with advanced solid malignancies. The survival advantages observed in the studies persist for months after the active treatment with LMWHs. Therefore these survival advantages are thought to be due to effects of LMWHs on tumor cell biology.

First line treatment of advanced NSCLC patients with the Cisplatin + Docetaxel combination has been widely studied, and is amongst the most active treatments currently available. The occurrence of grade 3/4 thrombopenia in several phase III trials was in the 0-3% range, making it an ideal chemotherapy regimen to combine with LMWHs in the treatment of advanced NSCLC.


Options:
A: Arm Label: Apixaban; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban
B: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: cisplatin + docetaxel | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: cisplatin + docetaxel + enoxaparin | Intervention Type: DRUG; Name: cisplatin + docetaxel; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: cisplatin + docetaxel + enoxaparin; Assigned to Arm(s): Arm B
C: Arm Label: Cohort 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 1: Apixaban, 5 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Cohort 1: Apixaban, 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Cohort 1: Apixaban, 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Cohort 2: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 2: Apixaban, 5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Cohort 1: Apixaban, 10 mg, Cohort 1: Apixaban, 20 mg, Cohort 1: Apixaban, 5 mg, Cohort 2: Apixaban, 5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1: Placebo, Cohort 2: Placebo
D: Arm Label: Group 1: Dalteparin; Type: EXPERIMENTAL; Interventions: Drug: Dalteparin | Arm Label: Group 2: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Group 1: Dalteparin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low Molecular Weight Heparin in Advanced Non Small Cell Lung Cancer (NSCLC): a Randomized Open Label Phase III Study Evaluating the Effect of Enoxaparin (Clexane) on Survival and Symptom Control in Patients With Stage IIIB and IV NSCLC Undergoing a Cisplatin Based First Line Chemotherapy: the SYRINGES Trial
Brief Summary: Rationale: a number of recent phase III randomized trials have shown a survival benefit of a treatment with subcutaneous low-molecular weight heparin in patients with advanced solid malignancies. The survival advantages observed in the studies persist for months after the active treatment with LMWHs. Therefore these survival advantages are thought to be due to effects of LMWHs on tumor cell biology.

First line treatment of advanced NSCLC patients with the Cisplatin + Docetaxel combination has been widely studied, and is amongst the most active treatments currently available. The occurrence of grade 3/4 thrombopenia in several phase III trials was in the 0-3% range, making it an ideal chemotherapy regimen to combine with LMWHs in the treatment of advanced NSCLC.


Options:
A: Arm Label: saline solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline solution (placebo) | Arm Label: nadroparin calcium; Type: EXPERIMENTAL; Interventions: Drug: Nadroparin calcium | Intervention Type: DRUG; Name: Nadroparin calcium; Assigned to Arm(s): nadroparin calcium | Intervention Type: DRUG; Name: saline solution (placebo); Assigned to Arm(s): saline solution
B: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Placebo drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo drug | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo drug; Assigned to Arm(s): Placebo drug
C: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin Sodium, Drug: Placebo | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin sodium, Drug: Placebo | Intervention Type: DRUG; Name: Semuloparin Sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Enoxaparin sodium; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Enoxaparin, Semuloparin
D: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: cisplatin + docetaxel | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: cisplatin + docetaxel + enoxaparin | Intervention Type: DRUG; Name: cisplatin + docetaxel; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: cisplatin + docetaxel + enoxaparin; Assigned to Arm(s): Arm B

Answer: D